Interesting Biotech / Biopharma Exits from IB? (not PE)

Based on the most helpful WSO content, here are some interesting exit opportunities for analysts in biotech/biopharma IB groups beyond the typical PE route:

1. Hedge Funds/Public Equity Biotech Roles:

   • There are hedge funds and public equity funds that focus specifically on biotech and biopharma. These roles often value the deal experience and industry exposure gained in a healthcare IB group. While a PhD or MD can be advantageous, it's not always a strict requirement, especially for roles focused on financial analysis rather than deep scientific research.

2. Late-Stage Venture Capital (VC):

   • Some late-stage VC funds hire directly from IB, particularly those with a focus on biotech and life sciences. These roles involve evaluating investment opportunities in companies that are closer to commercialization, which aligns well with the skills developed in IB.

3. Corporate Development/Strategy:

   • Many biotech and pharmaceutical companies have corporate development teams that focus on M&A, partnerships, and strategic initiatives. This is a natural transition for IB analysts, as the work is similar but within a corporate setting. These roles typically don't require a STEM background.

4. Startups and Entrepreneurship:

   • Some analysts leverage their industry knowledge and network to join or even start biotech-related startups. While this path is riskier, it can be highly rewarding for those with a strong interest in innovation and business development.

5. Specialized Consulting:

   • Consulting firms with a focus on life sciences and healthcare, such as LEK, ClearView, or ZS Associates, may value your IB experience. These roles often involve strategic advisory work for biotech and pharma clients.

6. Unique or Non-Traditional Exits:

   • While less common, there are examples of individuals pursuing unique paths, such as joining government agencies, non-profits focused on healthcare innovation, or even transitioning into roles in policy or advocacy within the biotech space.

While having a PhD or MD can open doors to certain roles, especially in early-stage VC or highly technical positions, your IB experience in a healthcare group provides a strong foundation for many buy-side and corporate opportunities. Networking and leveraging your deal experience will be key to exploring these paths.

Sources: Biotech finance: from IB to VC / HF to funded startup, Breakdown of Post-IB Exit Opportunities, Breakdown of Post-IB Exit Opportunities, A Few Observations on Investment Banking Exit Opportunities